News & Announcements
PD-L1 (22C3) IHC in TNBC
Integrated Oncology now expands the offering of the PD-L1 IHC (22C3) pharmDx assay for use in metastatic triple-negative breast cancer (TNBC) tumor samples. This companion diagnostic assay may help physicians determine which TNBC patients may benefit most with KEYTRUDA®(pembrolizumab) in combination with chemotherapy.
Leading Diagnostics Companies Join Forces to Establish the Access to Comprehensive Genomic Profiling Coalition (ACGP)
Seven leading diagnostics companies and laboratory service providers have formed the Access to Comprehensive Genomic Profiling Coalition (ACGP). The goal of the organization is to collectively advocate for appropriate broad U.S. health insurance coverage of comprehensive genomic profiling (CGP) for patients living with advanced cancer. The current members of ACGP are Exact Sciences, Foundation Medicine, Illumina, LabCorp, QIAGEN, Roche Diagnostics, and Thermo Fisher Scientific.
FDA approved, companion diagnostic, QIAGEN therascreen® PIK3CA mutation analysis assay for breast cancer is now available
The assay is intended to aid clinicians in identifying PIK3CA-mutated advanced or metastatic breast cancer patients who may be eligible for treatment with PIQRAY® (alpelisib). [Press Release]
FDA approved, companion diagnostic, QIAGEN therascreen® FGFR mutation analysis assay for locally advanced or metastatic urothelial carcinoma, is now available
The assay is used to assess the eligibility of patients for treatment with the newly approved FGFR kinase inhibitor, BALVERSA™ (erdafitinib), developed by Janssen Biotech, Inc. (Janssen). [Press Release]
NTRK Gene Fusions
TRK fusion proteins are oncogenic drivers that occur in a broad range of tumors across adult and pediatric cancers. Genomic profiling using either the OmniSeq AdvanceSM assay or the OmniSeq Comprehensive® assay can identify actionable NTRK gene fusions for TRK inhibitor treatment selection.
PD-L1 (SP142) IHC in TNBC
Integrated Oncology now expands the offering of the VENTANA PD-L1 (SP142) IHC assay for use in metastatic triple-negative breast cancer (TNBC) tumor samples. This companion diagnostic assay may help physicians determine which TNBC patients may benefit most with TECENTRIQ® (atezolizumab) plus chemotherapy.